S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

PYC Therapeutics Limited (PYC.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Phone61 8 6151 0992



Sales & Book Value

Annual Sales$62,500.00
Book ValueA$0.01 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive PYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PYC Therapeutics Limited (PYC.AX) (ASX:PYC) Frequently Asked Questions

What stocks does MarketBeat like better than PYC Therapeutics Limited (PYC.AX)?

Wall Street analysts have given PYC Therapeutics Limited (PYC.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PYC Therapeutics Limited (PYC.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of PYC Therapeutics Limited (PYC.AX)'s key competitors?

Who are PYC Therapeutics Limited (PYC.AX)'s key executives?

PYC Therapeutics Limited (PYC.AX)'s management team includes the following people:
  • Dr. Rohan Hockings MBBS, MBBS (Hons.), J.D., G.D.L.P, CEO & Director (Age 38, Pay $395k)
  • Mr. Kevin Hart B.Com., F.C.A., B.Com, FCA, Company Sec. & CFO (Age 59)
  • Prof. Sue Fletcher, Chief Scientific Officer
  • Mr. Sahm Nasseri M.B.A., MBA, CEO of US operations & Director (Age 37)
  • Mr. Kaggen Ausma L.L.B., Chief Bus. Officer
  • Dr. May Orfali, Chief Medical Officer of US Operations

What is PYC Therapeutics Limited (PYC.AX)'s stock symbol?

PYC Therapeutics Limited (PYC.AX) trades on the ASX under the ticker symbol "PYC."

How big of a company is PYC Therapeutics Limited (PYC.AX)?

PYC Therapeutics Limited (PYC.AX) has a market capitalization of $0.00 and generates $62,500.00 in revenue each year.

What is PYC Therapeutics Limited (PYC.AX)'s official website?

The official website for PYC Therapeutics Limited (PYC.AX) is pyctx.com.

How can I contact PYC Therapeutics Limited (PYC.AX)?

The company can be reached via phone at 61 8 6151 0992.

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.